Working... Menu

Translation and Clinical Implementation of a Test of Language and Short-term Memory in Aphasia. (Clinical TALSA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03635554
Recruitment Status : Recruiting
First Posted : August 17, 2018
Last Update Posted : August 20, 2018
University of Washington
Information provided by (Responsible Party):
Nadine Martin, Temple University

Brief Summary:
This project aims to develop a clinically feasible version of a laboratory-developed assessment battery for language and verbal short-term memory difficulties in aphasia.

Condition or disease

Detailed Description:

Over five years, we will develop a clinically feasible test that can be used to assess in-depth the language and verbal short-term memory abilities of individuals with aphasia (Called the TALSA - Temple Assessment of Language and Short-term memory in Aphasia. Based on a test that we have developed and tested over the past decade, we will create a shorter version that can be used by clinicians in a rehabilitation setting. The data to support this development will come from two sources: (1) clinicians in rehabilitation facilities who will use the new clinical test and provide feedback on the test (administration, value etc) and (2) people with aphasia who will be administered the longer version to help us identify the best test items in the laboratory version of the TALSA to be carried over to the shorter clinical version.

We are recruiting individuals with aphasia as well as people without aphasia (to serve as controls) to help with development of this assessment battery. The battery consists of between 15 and 20 subtests that assess many aspects of language and verbal short-term memory.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 150 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Translation and Clinical Implementation of a Test for Language and Short-term Memory in Aphasia.
Actual Study Start Date : December 15, 2017
Estimated Primary Completion Date : November 30, 2022
Estimated Study Completion Date : November 30, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Aphasia Memory

Primary Outcome Measures :
  1. Proportions correct on subtests of the Test of Language and Short-term Memory in Aphasia (TALSA) [ Time Frame: two to three years December 1, 2017 through December 15, 2017 through November 30, 2022. ]
    Participants will be administered 15-20 subtests of the TALSA that assess aspects of language (phoneme discrimination, sentence comprehension) and short-term memory (e.g., repetition span) abilities. Their responses on these measures will be evaluated in a item response analysis to determine which items are ideal to use in a smaller version of this test that is feasible to use in clinical practice. Another group of people with aphasia will be administered the clinical version (when it is complete) to develop normative data for that assessment battery.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Participants with aphasia will have single or multiple left hemisphere lesions, but no right hemisphere lesions. They can be between the ages of 21 and 80. Their aphasia can range in severity from mild to severe and can be of any type except global aphasia. Their language output can be fluent or nonfluent and their comprehension can be mild moderately impaired.

Inclusion Criteria:

  • . single or multiple left hemisphere lesions
  • at least one year post-stroke.
  • high-school educated
  • negative histories for mental illness and alcohol/substance abuse.
  • passed an audiometric pure-tone, air conduction screening at 25 dB HL at 1K, 2K and 4K Hz for at least one ear.

Exclusion Criteria:

English as a second language Right hemisphere stroke Less than 6 months post-onset of stroke.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03635554

Layout table for location contacts
Contact: Nadine Martin, Ph.D. 215 294 1870
Contact: Wendy Greenspan, MA 215-204-1790

Layout table for location information
United States, Pennsylvania
Temple University Recruiting
Philadelphia, Pennsylvania, United States, 19122
Contact: Nadine Martin, Ph.D.    215-204-1870   
Contact: Wendy Greenspan, MA    215 204 1790   
United States, Washington
University of Washington Recruiting
Seattle, Washington, United States, 98105
Contact: Diane Kendall, Ph.D.    206-616-0537   
Contact: JoAnn Silkes, Ph.D.    1 206 543-9005   
Sponsors and Collaborators
Temple University
University of Washington
Layout table for investigator information
Principal Investigator: Nadine Martin, Ph.D. Temple University

Layout table for additonal information
Responsible Party: Nadine Martin, Professor Communication Sciences and Disorders, Temple University Identifier: NCT03635554     History of Changes
Other Study ID Numbers: TempleU2
First Posted: August 17, 2018    Key Record Dates
Last Update Posted: August 20, 2018
Last Verified: August 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Nadine Martin, Temple University:

Additional relevant MeSH terms:
Layout table for MeSH terms
Speech Disorders
Language Disorders
Communication Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms